


Complete if Known



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket No.	98-385-I
-------	---	----	---	---------------------	----------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
EAT		6,294,352	B1	Hauptmann et al.	09-25-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
EAT	/	DE	3913101.7	A1	Boehringer Ingelheim International GmbH	04/29/1989		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
EAT	✓	HELLER et al., "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor", Proc. Natl. Acad. Sci. 87: 6151-55 (1990).	
	✓	PEPPEL et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," J. Exp. Med. 174:1483-89 (1991).	
	✓	POWELL et al., "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein specific T-cell clones correlates with encephalogenicity," Int. Immunol. 2:539-44 (1990).	
	✓	POWELL et al., "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. pgs 355-69.	
	✓	RHEIN et al., "Another Sepsis Drug Down-Immune TNF Receptor," Biotechnology Newswatch, pg. 1,3 (Monday, October 4, 1991)	
	✓	VILCEK et al., "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," J. Cell. Physiol. 5:57-61 (1987).	
✓	✓	SELMAJ et al., "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro," Ann. Neurol. 23(4):339-46 (1988).	


Examiner Signature	<i>Eileen B.O'Hara</i>	Date Considered	10/13/03
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

File Copy



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

4 Bide Street

2

of

?

Complete if Known

Application No.	09/898,234
Filing Date:	07/3/01
First Named Inventor	Hauptmann
Group Art Unit	1646
Examiner Name	E. O'Hara
Attorney Docket No.	98-385-I

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
ERA	✓	SELMAJ <i>et al.</i> , "Proliferation of Astrocytes In Vitro in Response to Cytokines: A Primary Role for Tumor Necrosis Factor," <i>J. Immunol.</i> 144(1):129-35 (1990).	
ERA	✓	SMITH <i>et al.</i> , "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>J. Biol. Chem.</i> 261(32):14871-74 (1986).	

Examiner Signature	Eileen B. O'Hara	Date Considered	10/13/03
-----------------------	------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231